Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $62 from $60 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in BioPharma. For Q3, investors will be centered on the Alimera (ALIM) acquisition following its delayed closure, and the firm’s main spotlight during the earnings call will be on the FDA warning letter received by Alimera’s manufacturing partner EyePoint Pharma (EYPT) and the steps needed for resolution, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals initiated with an Overweight at Piper Sandler
- ANI Pharmaceuticals announces FDA approval, launch of Ketoconazole Shampoo, 2%
- ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James
- ANI Pharmaceuticals completes acquisition of Alimera Sciences
- ANI Pharmaceuticals initiates closing of acquisition of Alimera Sciences